These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11596571)

  • 1. CF and antistaphylococcal prophylaxis.
    Smyth A; Walters S
    Thorax; 2001 Oct; 56(10):819-20. PubMed ID: 11596571
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence of new pathogens in CF: the devil we know or the devil we don't know?
    Burns JL
    J Pediatr; 2002 Mar; 140(3):283-4. PubMed ID: 11953721
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.
    Stutman HR; Lieberman JM; Nussbaum E; Marks MI
    J Pediatr; 2002 Mar; 140(3):299-305. PubMed ID: 11953726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On staphylococcal prophylaxis in CF.
    Wall M
    Pediatr Pulmonol; 2007 Feb; 42(2):186; author reply 187. PubMed ID: 17186506
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Staphylococcus aureus in cystic fibrosis.
    Elborn JS
    Thorax; 1999 May; 54(5):377-8. PubMed ID: 10212096
    [No Abstract]   [Full Text] [Related]  

  • 6. Early interventions in CF.
    Ratjen F
    Pediatr Pulmonol Suppl; 2004; 26():88-90. PubMed ID: 15029609
    [No Abstract]   [Full Text] [Related]  

  • 7. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
    Smyth AR; Walters S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD001912. PubMed ID: 23235585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palivizumab prophylaxis in infants with cystic fibrosis does not delay first isolation of Pseudomonas aeruginosa or Staphylococcus aureus.
    Buchs C; Dalphin ML; Sanchez S; Perceval M; Coutier L; Mainguy C; Kassaï-Koupaï B; Reix P
    Eur J Pediatr; 2017 Jul; 176(7):891-897. PubMed ID: 28508992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis.
    McCaffery K; Olver RE; Franklin M; Mukhopadhyay S
    Thorax; 1999 May; 54(5):380-3. PubMed ID: 10212099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind comparison of cephradine and cephalexin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus.
    Hubsher JA; Gadebusch HH; Itkin AG
    Curr Ther Res Clin Exp; 1976 Jun; 19(6):579-88. PubMed ID: 819217
    [No Abstract]   [Full Text] [Related]  

  • 11. Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.
    Monogue ML; Pettit RS; Muhlebach M; Cies JJ; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6578-6584. PubMed ID: 27550351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infection prevention and control in cystic fibrosis.
    Saiman L
    Curr Opin Infect Dis; 2011 Aug; 24(4):390-5. PubMed ID: 21543979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis.
    Harrison CJ; Marks MI; Welch DF; Sharma BB; Baker D; Dice J
    Pediatr Pharmacol (New York); 1985; 5(1):7-16. PubMed ID: 3921934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cephalexin pharmacokinetics in patients with cystic fibrosis.
    Nahata MC; Lubin AH; Visconti JA
    Dev Pharmacol Ther; 1984; 7(4):221-8. PubMed ID: 6468223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis.
    Wright GL; Harper J
    Lancet; 1970 Jan; 1(7636):9-14. PubMed ID: 4188384
    [No Abstract]   [Full Text] [Related]  

  • 16. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?
    Smyth A
    Pediatr Pulmonol; 2005 Dec; 40(6):471-6. PubMed ID: 16200640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G; Petraru E; Dahorea C; Anton DT
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cephalosporin antibiotics in clinical medicine.
    Seftel HC
    S Afr Med J; 1973 Mar; 47(10):442-7. PubMed ID: 4486963
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
    Nadesalingam K; Conway SP; Denton M
    J Cyst Fibros; 2005 Mar; 4(1):49-52. PubMed ID: 15752681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of Candida dubliniensis in lower respiratory tract secretions from cystic fibrosis patients may be related to increased adherence properties.
    Wahab AA; Taj-Aldeen SJ; Kolecka A; ElGindi M; Finkel JS; Boekhout T
    Int J Infect Dis; 2014 Jul; 24():14-9. PubMed ID: 24780917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.